United Financial Statements From 2010 to 2024

UTHR Stock  USD 243.27  4.59  1.85%   
United Therapeutics financial statements provide useful quarterly and yearly information to potential United Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on United Therapeutics financial statements helps investors assess United Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting United Therapeutics' valuation are summarized below:
Gross Profit
1.8 B
Profit Margin
0.4231
Market Capitalization
11.4 B
Enterprise Value Revenue
4.0259
Revenue
2.3 B
There are over one hundred nineteen available fundamental trend indicators for United Therapeutics, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to double-check United Therapeutics' current fundamental performance against the performance between 2010 and 2024 to make sure the trends are evolving in the right direction.
Check United Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among United main balance sheet or income statement drivers, such as Depreciation And Amortization of 55.9 M, Total Revenue of 2.4 B or Gross Profit of 2.2 B, as well as many exotic indicators such as Short Term Coverage Ratios of 2.67, Price Earnings Ratio of 12.23 or Price To Sales Ratio of 4.46. United financial statements analysis is a perfect complement when working with United Therapeutics Valuation or Volatility modules.
  
This module can also supplement United Therapeutics' financial leverage analysis and stock options assessment as well as various United Therapeutics Technical models . Check out the analysis of United Therapeutics Correlation against competitors.
To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.

United Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets7.5 B7.2 B3.5 B
Slightly volatile
Short and Long Term Debt Total735 M700 M421.5 M
Slightly volatile
Other Current Liabilities116.3 M71 M175.1 M
Slightly volatile
Total Current Liabilities844.6 M804.4 M410.8 M
Slightly volatile
Total Stockholder Equity6.3 BB2.7 B
Slightly volatile
Property Plant And Equipment Net1.1 BB616.7 M
Slightly volatile
Accounts Payable10.2 M5.6 M10.5 M
Slightly volatile
Cash1.3 B1.2 B669.2 M
Slightly volatile
Non Current Assets Total3.8 B3.6 B1.8 B
Slightly volatile
Non Currrent Assets Other91.5 M151.8 M119.7 M
Slightly volatile
Cash And Short Term Investments3.1 BB1.8 B
Slightly volatile
Net Receivables292.8 M278.9 M178.3 M
Slightly volatile
Common Stock Shares Outstanding50.7 M49.7 M47.2 M
Pretty Stable
Liabilities And Stockholders Equity7.5 B7.2 B3.5 B
Slightly volatile
Non Current Liabilities Total269.4 M377.8 M390 M
Slightly volatile
Other Current Assets174.5 M166.2 M86.4 M
Slightly volatile
Total Liabilities1.2 B1.2 B811.9 M
Slightly volatile
Total Current Assets3.7 B3.6 B1.7 B
Slightly volatile
Good Will35.4 M33.7 M19.3 M
Slightly volatile
Common Stock Total Equity531.1 K805 K643.5 K
Slightly volatile
Short Term Investments1.9 B1.8 B723 M
Slightly volatile
Property Plant And Equipment Gross1.5 B1.5 B723.7 M
Slightly volatile
Short Term Debt483 M460 M274.8 M
Slightly volatile
Intangible Assets84.5 M80.5 M47.8 M
Slightly volatile
Common Stock540.6 K805 K644.1 K
Slightly volatile
Other Liabilities60.5 M88.3 M87.5 M
Very volatile
Other Assets284.7 M475.5 M379.8 M
Slightly volatile
Inventory55.9 M111.8 M75.6 M
Slightly volatile
Property Plant EquipmentB990.7 M609.5 M
Slightly volatile
Current Deferred Revenue395.8 M377 M284.3 M
Pretty Stable
Preferred Stock Total Equity17.5 M22.1 M18.5 M
Pretty Stable
Net Tangible Assets5.7 B5.5 B2.6 B
Slightly volatile
Warrants20 M22.1 M20.1 M
Very volatile
Long Term Debt Total469.1 M920 M398.7 M
Slightly volatile
Capital Surpluse1.9 B2.7 B1.8 B
Slightly volatile
Long Term InvestmentsB1.9 B752 M
Slightly volatile
Non Current Liabilities Other98.1 M77.8 M93.6 M
Very volatile
Deferred Long Term Asset Charges133.2 M86.1 M143.5 M
Slightly volatile
Short and Long Term Debt483 M460 M252 M
Slightly volatile
Net Invested Capital4.8 B6.7 B3.4 B
Slightly volatile
Net Working Capital2.1 B2.7 B1.5 B
Slightly volatile
Capital Stock598.5 K630 K12.2 M
Slightly volatile

United Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue2.4 B2.3 B1.5 B
Slightly volatile
Gross Profit2.2 B2.1 B1.3 B
Slightly volatile
Other Operating Expenses1.2 B1.1 B819.2 M
Slightly volatile
Research Development239.6 M408 M331.5 M
Slightly volatile
Total Operating Expenses469.6 M885.1 M659.7 M
Slightly volatile
Selling General Administrative207.3 M395.3 M279 M
Slightly volatile
Cost Of Revenue270.4 M257.5 M129 M
Slightly volatile
Selling And Marketing Expenses77.7 M81.8 M295 M
Slightly volatile
Discontinued Operations5.6 K6.3 K6.9 K
Slightly volatile
Interest Income170.8 M162.7 M35.9 M
Slightly volatile
Reconciled Depreciation49.8 M53.2 M38.9 M
Slightly volatile

United Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash FlowB961.2 M588.5 M
Slightly volatile
Capital Expenditures241.9 M230.4 M97.8 M
Slightly volatile
End Period Cash Flow1.3 B1.2 B670.6 M
Slightly volatile
Issuance Of Capital Stock3.1 M3.5 M3.8 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.464.695471.7145
Slightly volatile
Dividend Yield0.00870.0090.0056
Pretty Stable
Operating Cycle192202347
Slightly volatile
Price Book Value Ratio1.731.8263.0477
Slightly volatile
Days Of Payables Outstanding7.547.937973.1449
Slightly volatile
Inventory Turnover1.192.30321.5747
Pretty Stable
Ebt Per Ebit1.191.07541.0344
Pretty Stable
Payables Turnover48.2845.982119.4409
Slightly volatile
Effective Tax Rate0.240.22720.2806
Very volatile
Company Equity Multiplier1.11.19751.342
Slightly volatile
Long Term Debt To Capitalization0.080.04770.1137
Pretty Stable
Cash Per Share63.2660.243529.4384
Slightly volatile
Total Debt To Capitalization0.120.10470.1279
Pretty Stable
Debt Equity Ratio0.180.1170.1554
Pretty Stable
Quick Ratio6.474.06894.2296
Slightly volatile
Net Income Per E B T0.920.77280.7304
Pretty Stable
Cash Ratio1.431.50141.8746
Pretty Stable
Days Of Inventory Outstanding151158278
Pretty Stable
Days Of Sales Outstanding84.2543.737372.3133
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.080.76440.9057
Very volatile
Price To Book Ratio1.731.8263.0477
Slightly volatile
Current Ratio7.294.41455.0489
Slightly volatile
Fixed Asset Turnover1.892.22642.2297
Pretty Stable
Debt Ratio0.10.09770.1095
Pretty Stable
Price Sales Ratio4.464.695471.7145
Slightly volatile
Receivables Turnover5.578.34537.6129
Slightly volatile
Asset Turnover0.290.32480.4444
Pretty Stable
Price Fair Value1.731.8263.0477
Slightly volatile

United Fundamental Market Drivers

Forward Price Earnings10.8342
Cash And Short Term InvestmentsB

United Upcoming Events

28th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About United Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include United Therapeutics income statement, its balance sheet, and the statement of cash flows. United Therapeutics investors use historical funamental indicators, such as United Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although United Therapeutics investors may use each financial statement separately, they are all related. The changes in United Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on United Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on United Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in United Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2024
Current Deferred Revenue377 M395.8 M
Total Revenue2.3 B2.4 B
Cost Of Revenue257.5 M270.4 M
Ebit Per Revenue 0.51  0.53 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether United Therapeutics is a strong investment it is important to analyze United Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact United Therapeutics' future performance. For an informed investment choice regarding United Stock, refer to the following important reports:
Check out the analysis of United Therapeutics Correlation against competitors.
To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.
Note that the United Therapeutics information on this page should be used as a complementary analysis to other United Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for United Stock analysis

When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Equity Valuation
Check real value of public entities based on technical and fundamental data
Is United Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of United Therapeutics. If investors know United will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about United Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.626
Earnings Share
19.8
Revenue Per Share
49.733
Quarterly Revenue Growth
0.251
Return On Assets
0.1122
The market value of United Therapeutics is measured differently than its book value, which is the value of United that is recorded on the company's balance sheet. Investors also form their own opinion of United Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is United Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because United Therapeutics' market value can be influenced by many factors that don't directly affect United Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between United Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if United Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, United Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.